Ganglioneuroblastoma Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Ganglioneuroblastoma (morphologic abnormality) / Ganglioneuroblastoma (disorder)

IndicationStatusPhase
DBCOND0002891 (Ganglioneuroblastoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01767194Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaTreatment